Skip to Content
Merck
  • Shifts in the Skin Microbiota after UVB Treatment in Adult Atopic Dermatitis.

Shifts in the Skin Microbiota after UVB Treatment in Adult Atopic Dermatitis.

Dermatology (Basel, Switzerland) (2021-04-23)
Astrid Haaskjold Lossius, Olav Sundnes, Anna Cäcilia Ingham, Sofie Marie Edslev, Jørgen Vildershøj Bjørnholt, Berit Lilje, Maria Bradley, Samina Asad, Guttorm Haraldsen, Paal Skytt-Andersen, Jan-Øivind Holm, Teresa Løvold Berents
ABSTRACT

The pathophysiology in atopic dermatitis (AD) is not fully understood, but immune dysfunction, skin barrier defects, and alterations of the skin microbiota are thought to play important roles. AD skin is frequently colonized with Staphylococcus aureus (S. aureus) and microbial diversity on lesional skin (LS) is reduced compared to on healthy skin. Treatment with narrow-band ultraviolet B (nb-UVB) leads to clinical improvement of the eczema and reduced abundance of S. aureus. However, in-depth knowledge of the temporal dynamics of the skin microbiota in AD in response to nb-UVB treatment is lacking and could provide important clues to decipher whether the microbial changes are primary drivers of the disease, or secondary to the inflammatory process. To map the temporal shifts in the microbiota of the skin, nose, and throat in adult AD patients after nb-UVB treatment. Skin swabs were taken from lesional AD skin (n = 16) before and after 3 treatments of nb-UVB, and after 6-8 weeks of full-body treatment. We also obtained samples from non-lesional skin (NLS) and from the nose and throat. All samples were characterized by 16S rRNA gene sequencing. We observed shifts towards higher diversity in the microbiota of lesional AD skin after 6-8 weeks of treatment, while the microbiota of NLS and of the nose/throat remained unchanged. After only 3 treatments with nb-UVB, there were no significant changes in the microbiota. Nb-UVB induces changes in the skin microbiota towards higher diversity, but the microbiota of the nose and throat are not altered.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Mutanolysin from Streptomyces globisporus ATCC 21553, free of DNA contaminants, suitable for Microbiome research, lyophilized powder, ≥4000 units/mg protein (biuret)
Roche
Proteinase K, recombinant, PCR Grade, Solution from Pichia pastoris
Sigma-Aldrich
Lysostaphin from Staphylococcus staphylolyticus, free of DNA contaminants, suitable for Microbiome research, lyophilized powder, ≥500 units/mg protein